Cargando…

P1457: DEMOGRAPHICS AND TREATMENT OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH OFF-THE-SHELF EBV-SPECIFIC CTL (TABELECLEUCEL) UNDER AN ONGOING EXPANDED ACCESS PROGRAM IN EUROPE: FIRST ANALYSES

Detalles Bibliográficos
Autores principales:	Choquet, S., Uttenthal, B., Chaganti, S., Comoli, P., Trappe, R., Friedetzky, A., Xing, B., Li, X., Polak, T., Gamelin, L., Terwey, J.-H., Dierickx, D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429700/ http://dx.doi.org/10.1097/01.HS9.0000848684.24968.42

Ejemplares similares

P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE
por: Choquet, Sylvain, et al.
Publicado: (2023)

Expert Consensus on the Characteristics of Patients with Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV(+) PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study
por: Chaganti, Sridhar, et al.
Publicado: (2023)

P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN-LABEL GLOBAL PHASE3 STUDY OF TAB-CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE)
por: Kris Michael, Mahadeo, et al.
Publicado: (2023)

HLA-E–restricted immune responses are crucial for the control of EBV infections and the prevention of PTLD
por: Vietzen, Hannes, et al.
Publicado: (2023)

P1107: CLINICAL OUTCOMES OF SOLID ORGAN TRANSPLANT PATIENTS WITH EBV+ PTLD WHO FAIL RITUXIMAB PLUS CHEMOTHERAPY: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY
por: Dharnidharka, V., et al.
Publicado: (2022)

Lytic EBV infection investigated by detection of Soluble Epstein-Barr virus ZEBRA in the serum of patients with PTLD
por: Habib, Mohammed, et al.
Publicado: (2017)

Use of Foscarnet Therapy for EBV Infection following Control of PTLD with Enhancement of Cellular Immunity in a Lung-Transplant Recipient
por: Afshar, Kamyar, et al.
Publicado: (2011)

P1339: CLINICAL OUTCOMES OF PATIENTS WITH EBV+ PTLD FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION WHO FAIL RITUXIMAB: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY
por: Sanz-Caballer, J., et al.
Publicado: (2022)

The Cycle of EBV Infection Explains Persistence, the Sizes of the Infected Cell Populations and Which Come under CTL Regulation
por: Hawkins, Jared B., et al.
Publicado: (2013)

Antiviral Drugs for EBV
por: Pagano, Joseph S., et al.
Publicado: (2018)

EBV & lymphoma
por: Caballero, Dolores
Publicado: (2019)

EBV and Lymphomagenesis
por: Sausen, Daniel G., et al.
Publicado: (2023)

The Role of NK Cells in EBV Infection and EBV-Associated NPC
por: Png, Yi Tian, et al.
Publicado: (2021)

EBV-induced T-cell responses in EBV-specific and nonspecific cancers
por: Zhang, Qiuting, et al.
Publicado: (2023)

The EBV Gastric Cancer Resource (EBV-GCR): A Suite of Tools for Investigating EBV-Associated Human Gastric Carcinogenesis
por: Salnikov, Mikhail Y., et al.
Publicado: (2023)

Analysis of Post-Transplant Lymphoproliferative Disorder (PTLD) Outcomes with Epstein–Barr Virus (EBV) Assessments—A Single Tertiary Referral Center Experience and Review of Literature
por: Lau, Eric, et al.
Publicado: (2021)

Curcuminoids as EBV Lytic Activators for Adjuvant Treatment in EBV-Positive Carcinomas
por: Ramayanti, Octavia, et al.
Publicado: (2018)

The role of EBV-encoded miRNA in EBV-associated gastric cancer
por: Liu, Ting, et al.
Publicado: (2023)

Opportunities to Target the Life Cycle of Epstein-Barr Virus (EBV) in EBV-Associated Lymphoproliferative Disorders
por: Dugan, James P., et al.
Publicado: (2019)

EBV in Hodgkin Lymphoma
por: Massini, Giuseppina, et al.
Publicado: (2009)

EBV Chronic Infections
por: Eligio, Pizzigallo, et al.
Publicado: (2010)

EBV and human cancer
por: Ko, Young-Hyeh
Publicado: (2015)

Progress in EBV Vaccines
por: van Zyl, Dwain G., et al.
Publicado: (2019)

From Anti-EBV Immune Responses to the EBV Diseasome via Cross-reactivity
por: Kanduc, Darja, et al.
Publicado: (2020)

Plasma EBV DNA as a prognostic factor in EBV associated gastric cancer: a multicenter, prospective study (EBV PRESAGE study)
por: Alberti, Andrea, et al.
Publicado: (2023)

ADA2 deficiency complicated by EBV-driven lymphoproliferative disease
por: Staples, Emily, et al.
Publicado: (2020)

The Characteristics of Epstein‐Barr Virus (EBV)‐positive Diffuse Large B‐Cell Lymphoma: Comparison between EBV(+) and EBV(‐) Cases in Japanese Population
por: Kuze, Tetuo, et al.
Publicado: (2000)

Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas
por: Mundo, Lucia, et al.
Publicado: (2020)

'Off-the-shelf’ allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies
por: Sinha, Debottam, et al.
Publicado: (2021)

Resveratrol Prevents EBV Transformation and Inhibits the Outgrowth of EBV-Immortalized Human B Cells
por: Espinoza, J. Luis, et al.
Publicado: (2012)

Age-related EBV positive clonal B-cell Lymphoid proliferation (EBV+-DLBCL)
por: Georgakopoulou, Eleni, et al.
Publicado: (2017)

Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV
por: Venturini, Cristina, et al.
Publicado: (2021)

1457. Escherichia coli Community Acquired Pneumonia
por: John, Teny Mathew, et al.
Publicado: (2018)

Correction: Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas
por: Mundo, Lucia, et al.
Publicado: (2020)

EBV covers its tracks
por: Bashyam, Hema
Publicado: (2007)

EBV and HIV-Related Lymphoma
por: Bibas, Michele, et al.
Publicado: (2009)

EBV takes a toll
por: Leslie, Mitch
Publicado: (2009)

Preventing EBV immune evasion
Publicado: (2014)

The EBV action in tonsils and adenoids
por: Endo, L.H., et al.
Publicado: (2003)

HSV-tk/GCV gene therapy mediated by EBV-LMP1 for EBV-associated cancer
por: Lifang, Yang, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_brvabruiaqvid1ac1bjdd2ak39